• Mohammad Almohideb.
• King Saud bin Abdulaziz University for Health Sciences, College of Medicine, Riyadh, Saudi Arabia.
• Medicine (Baltimore). 2022 Sep 2; 101 (35): e29390e29390.

BackgroundMelanoma is a cancerous tumor that develops from melanocytes in the epidermal basal layer of the skin. It is a fatal skin cancer and the third most common kind of cutaneous tumor. We aim to evaluate the effect of nivolumab in melanoma patients compared with other regimens.MethodsThis meta-analysis included only clinical trials, both randomized and nonrandomized. The main outcomes of interest were the response to treatment, overall survival (OS), progression-free survival, and adverse events.ResultsThe overall effect estimates favored nivolumab group over the combination of nivolumab plus ipilimumab (HR 3.06, 95% CI 1.70-5.49) and chemotherapy group (HR 3.58, 95% CI 1.63-7.84) after 1 year. Compared to chemotherapy, nivolumab had lower rates of adverse events.ConclusionNivolumab monotherapy yields high progression-free survival rates and has the same efficacy when combined with ipilimumab in a 1-year OS. However, after 2 and 3 years of follow-up, the combined regimen has more OS rates.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

12 keywords...

hide…